IMGN のPS 比率は同業他社と比較してどうか。

IMGNは、同業他社の平均 ( { 29.1 x) と比較したPrice-To-Sales比率 ( 6.8 x) に基づいて高価です。

IMGN'のPS レシオは、US Biotechs 業界の他社と比較してどうか。

IMGNは、 US Biotechs業界平均 (13x) (29.1 x) と比較すると、 Price-To-Sales比率 ( 13 x) に基づくと高価です。

IMGN'のPS レシオとフェアPS レシオを比較すると？これは、会社の予想利益成長率、利益率、その他のリスク要因を考慮した予想PS レシオです。

IMGNは、推定される公正Price-To-Sales比率 ( 29.1 x) と比較して、そのPrice-To-Sales比率 ( 7.9 x) に基づくと高価です。

IMGN 、その将来キャッシュフローを見たときの公正価格はいくらになるだろうか？この見積もりには、割引キャッシュフローモデルを使用します。

IMGN ( $31.23 ) は、当社の [[公正価値]] の見積もり ( $29.31 ) を上回って取引されています。

アナリストの12ヶ月の予想と、コンセンサス目標株価に対する統計的信頼性は？

目標株価は現在の株価よりも低いです。

ImmunoGen ( ) - 株価, ニュースと分析Nasdaq:IMGN

Q: アナリストの12ヶ月の予想と、コンセンサス目標株価に対する統計的信頼性は？

目標株価は現在の株価よりも低いです。

IMGN 株式概要

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients.

会社概要

IMGN ファンダメンタル分析
スノーフレーク・スコア
評価	0/6
将来の成長	6/6
過去の実績	0/6
財務の健全性	4/6
配当金	0/6

報酬

収益は年間45.85%増加すると予測されています

リスク分析

過去3か月間の株価の変動は非常に激しい

過去1年間で株主の希薄化が進んだ

ImmunoGen, Inc. 競合他社

Halozyme Therapeutics

NasdaqGS:HALO

US$7.3b

Exelixis

NasdaqGS:EXEL

US$9.7b

Insmed

NasdaqGS:INSM

US$12.2b

Neurocrine Biosciences

NasdaqGS:NBIX

US$12.4b

価格と性能

の歴代最高値、変動、値下がりまとめImmunoGen
過去の株価
現在の株価	US$31.23
52週高値	US$31.25
52週安値	US$3.61
ベータ	1.17
11ヶ月の変化	4.94%
3ヶ月変化	98.16%
1年変化	617.93%
33年間の変化	196.58%
5年間の変化	452.74%
IPOからの変化	228.74%

Final Countdown: AbbVie's Imminent Closure With ImmunoGen And What It Means

Feb 09

Recent updates

Final Countdown: AbbVie's Imminent Closure With ImmunoGen And What It Means

Feb 09

ImmunoGen, Inc.'s (NASDAQ:IMGN) Intrinsic Value Is Potentially 40% Above Its Share Price

Jan 09

There's Reason For Concern Over ImmunoGen, Inc.'s (NASDAQ:IMGN) Massive 95% Price Jump

Dec 22

ImmunoGen (NASDAQ:IMGN) Is Using Debt Safely

Oct 20

Analysts Just Made A Massive Upgrade To Their ImmunoGen, Inc. (NASDAQ:IMGN) Forecasts

Aug 06

Is ImmunoGen, Inc. (NASDAQ:IMGN) Trading At A 48% Discount?

Jul 20

Forecast: Analysts Think ImmunoGen, Inc.'s (NASDAQ:IMGN) Business Prospects Have Improved Drastically

May 03

ImmunoGen, Inc.'s (NASDAQ:IMGN) Low P/S No Reason For Excitement

Apr 18

Is ImmunoGen (NASDAQ:IMGN) In A Good Position To Deliver On Growth Plans?

Feb 25

What Does The Future Hold For ImmunoGen, Inc. (NASDAQ:IMGN)? These Analysts Have Been Cutting Their Estimates

Jan 03

株主還元

	IMGN	US Biotechs	US 市場
7D	6.6%	-1.4%	-1.9%
1Y	617.9%	20.2%	30.4%

業界別リターン: IMGN過去 1 年間で20.2 % の収益を上げたUS Biotechs業界を上回りました。

リターン対市場: IMGN過去 1 年間で30.4 % の収益を上げたUS市場を上回りました。

価格変動

Is IMGN's price volatile compared to industry and market?
IMGN volatility
IMGN Average Weekly Movement	24.0%
Biotechs Industry Average Movement	9.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	2.9%

安定した株価: IMGNの株価は過去 3 か月間にわたって変動しています。

時間の経過による変動: IMGNの weekly volatility ( 24% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。

会社概要

設立	従業員	CEO（最高経営責任者	ウェブサイト
1980	277	Mark Enyedy	www.immunogen.com

ImmunoGen, Inc. 基礎のまとめ

ImmunoGen の収益と売上を時価総額と比較するとどうか。
IMGN 基礎統計学
時価総額	US$8.36b
収益（TTM）	-US$73.52m
売上高(TTM)	US$287.61m

29.1x

P/Sレシオ

-113.7x

PER（株価収益率

IMGN は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
IMGN 損益計算書（TTM）
収益	US$287.61m
売上原価	US$211.62m
売上総利益	US$76.00m
その他の費用	US$149.52m
収益	-US$73.52m

直近の収益報告

Sep 30, 2023

次回決算日

該当なし

一株当たり利益（EPS）	-0.27
グロス・マージン	26.42%
純利益率	-25.56%
有利子負債／自己資本比率	12.8%

IMGN の長期的なパフォーマンスは？

過去の実績と比較を見る

IMGN 株式概要

報酬

リスク分析

ImmunoGen, Inc. 競合他社

NasdaqGS:HALO

US$7.3b

NasdaqGS:EXEL

US$9.7b

NasdaqGS:INSM

US$12.2b

NasdaqGS:NBIX

US$12.4b

価格と性能

最新ニュース

ImmunoGen Files Form 15

ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from NASDAQ Composite Index

AbbVie Inc. (NYSE:ABBV) completed the acquisition of ImmunoGen, Inc. (NasdaqGS:IMGN) from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc. (NYSE:BLK), State Street Corporation (NYSE:STT), The Vanguard Group, Inc. and others.

Final Countdown: AbbVie's Imminent Closure With ImmunoGen And What It Means

President notifies of intention to sell stock

Insider notifies of intention to sell stock

Recent updates

ImmunoGen Files Form 15

ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from NASDAQ Composite Index

AbbVie Inc. (NYSE:ABBV) completed the acquisition of ImmunoGen, Inc. (NasdaqGS:IMGN) from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc. (NYSE:BLK), State Street Corporation (NYSE:STT), The Vanguard Group, Inc. and others.

Final Countdown: AbbVie's Imminent Closure With ImmunoGen And What It Means

President notifies of intention to sell stock

Insider notifies of intention to sell stock

ImmunoGen, Inc.'s (NASDAQ:IMGN) Intrinsic Value Is Potentially 40% Above Its Share Price

Forecast breakeven date pushed back to 2024

There's Reason For Concern Over ImmunoGen, Inc.'s (NASDAQ:IMGN) Massive 95% Price Jump

Insider notifies of intention to sell stock

ImmunoGen, Inc. Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH

FDA Grants Priority Review of ImmunoGen, Inc.'s Supplemental Biologics License Application for ELAHERE in Platinum-Resistant Ovarian Cancer

Insider exercised options and sold US$3.0m worth of stock

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.5 billion.

New major risk - Share price stability

Price target increased by 10% to US$25.39

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.4 billion.

Insider recently sold US$1.5m worth of stock

Forecast breakeven date moved forward to 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

ImmunoGen Announces European Medicines Agency Acceptance of Marketing Authorization Application for Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer

ImmunoGen (NASDAQ:IMGN) Is Using Debt Safely

Insider exercised options and sold US$1.9m worth of stock

Insider recently sold US$1.3m worth of stock

ImmunoGen, Inc. Announces Executive Changes

Insider notifies of intention to sell stock

Analysts Just Made A Massive Upgrade To Their ImmunoGen, Inc. (NASDAQ:IMGN) Forecasts

President recently sold US$17m worth of stock

Immunogen, Inc. Reaffirmes Revenue Guidance for 2023

Forecast breakeven date moved forward to 2024

ImmunoGen, Inc. Announces Executive Changes

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 8.0% to US$19.00

Is ImmunoGen, Inc. (NASDAQ:IMGN) Trading At A 48% Discount?

Price target increased by 13% to US$16.20

ImmunoGen Inc. Presents Updated Findings from CADENZA Trial of Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm at EHA 2023 Congress

ImmunoGen Inc. Announces Detailed Results from the Phase 3 Confirmatory MIRASOL Trial (GOG 3045/ENGOT OV-55) Evaluating the Safety and ELAHERE

Consensus revenue estimates increase by 80%

ImmunoGen, Inc. Announces ELAHERE Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRa-Positive Platinum-Resistant Ovarian Cancer

Price target increased by 18% to US$14.10

Forecast: Analysts Think ImmunoGen, Inc.'s (NASDAQ:IMGN) Business Prospects Have Improved Drastically

Forecast to breakeven in 2025

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

ImmunoGen, Inc.'s (NASDAQ:IMGN) Low P/S No Reason For Excitement

No longer forecast to breakeven

Consensus EPS estimates upgraded to US$0.80 loss, revenue downgraded

Full year 2022 earnings released: US$0.88 loss per share (vs US$0.68 loss in FY 2021)

Forecast to breakeven in 2025

Is ImmunoGen (NASDAQ:IMGN) In A Good Position To Deliver On Growth Plans?

Immunogen, Inc. Appoints Michael Vasconcelles as Executive Vice President, Research, Development, and Medical Affairs

What Does The Future Hold For ImmunoGen, Inc. (NASDAQ:IMGN)? These Analysts Have Been Cutting Their Estimates

ImmunoGen, Inc. Announces Executive Changes

ImmunoGen, Inc. Presents Findings from Expansion Cohorts in Phase 1b/2 Study of Pivekimab Sunirine with Vidaza® and Venclexta® in Acute Myeloid Leukemia at ASH

ImmunoGen, Inc. Appoints Daniel Char as Senior Vice President and Chief Legal Officer

NeoGenomics and ImmunoGen Launches New Program Giving Ovarian Cancer Patients Access to Novel Fr Biomarker Testing to Support the Launch of Elahere(Tm)

株主還元

価格変動

会社概要

ImmunoGen, Inc. 基礎のまとめ